Fertility Preservation Options Before Gynecologic Cancer Treatment
Posted on June 29, 2026 in Cancer Information
Written by Davis, Holly
A gynecologic cancer diagnosis brings an overwhelming number of decisions, often all at once. For patients of reproductive age, one of the most important and time-sensitive questions is whether the ability to have biological children can be protected before treatment begins.
Many cancer treatments, including chemotherapy, pelvic radiation, and certain surgeries, can affect fertility. The encouraging reality is that fertility preservation has advanced significantly, and several proven options exist. The catch is timing: most of these options work best, and some only work at all, when they are arranged before cancer treatment starts.
Below, you’ll learn how gynecologic cancer treatment can affect fertility, what preservation options are available, and why an early conversation with your care team matters so much.
Jump to section
- How Cancer Treatment Affects Fertility
- Why Timing Matters
- Fertility Preservation Options
- Fertility-Sparing Surgery
- Questions to Ask Your Care Team
- SERO’s Role
- Frequently Asked Questions
How Cancer Treatment Affects Fertility
The effect on fertility depends on the type of gynecologic cancer, its stage, and the specific treatments involved.
Chemotherapy can damage the ovaries and the eggs they contain. The degree of risk varies by drug and dose; for platinum-based chemotherapy, one commonly cited estimate places the rate of ovarian failure at around 20% to 30%.
Pelvic radiation therapy carries an even higher risk to ovarian function when the ovaries sit within the treatment field, with reported rates of ovarian failure ranging up to 75% to 100%. Radiation can also affect the uterus, which has implications for carrying a future pregnancy.
Surgery for gynecologic cancer can affect fertility directly when it involves removing the uterus, ovaries, or other reproductive organs. In some early-stage cancers, however, surgical approaches that preserve these organs may be an option, which we’ll cover below.
Why Timing Matters
The single most important thing to understand about fertility preservation is that it is most effective when arranged before cancer treatment begins.
According to the American Society of Clinical Oncology, fertility risks should be discussed with patients at the time of diagnosis, and these conversations can happen alongside staging and treatment planning rather than after. ASCO recommends that patients who are interested in or unsure about fertility preservation be referred to a reproductive specialist and that preservation approaches be discussed before cancer-directed therapy starts.
Part of the reason is practical. Egg and embryo freezing require ovarian stimulation, a process that generally takes at least two to four weeks. Building that window into the treatment timeline requires planning, which is why raising the topic early gives you the widest set of choices.
Fertility Preservation Options
ASCO identifies several established fertility preservation methods for women, including embryo cryopreservation, egg (oocyte) cryopreservation, ovarian tissue cryopreservation, ovarian transposition, and conservative gynecologic surgery.
Egg (Oocyte) Cryopreservation
Egg freezing involves stimulating the ovaries with medication, retrieving mature eggs, and freezing them for future use. ASCO considers oocyte cryopreservation a standard, widely available option. It does not require a partner or donor sperm, which makes it a flexible choice for many patients.
Embryo Cryopreservation
Embryo freezing follows the same stimulation and retrieval process, after which the retrieved eggs are fertilized with sperm and the resulting embryos are frozen. Like egg freezing, embryo cryopreservation is a standard, well-established method. The choice between freezing eggs or embryos depends on personal circumstances and preferences, including whether you have a partner or wish to use donor sperm.
For cancers that are sensitive to estrogen, there has historically been concern about the hormones involved in ovarian stimulation. Protocols that combine the drug letrozole with standard fertility medication can stimulate the ovaries without causing estrogen to spike, and the number of eggs and embryos produced this way appears comparable to standard stimulation.
Ovarian Tissue Cryopreservation
This approach involves surgically removing ovarian tissue, freezing it, and transplanting it back later. One advantage is that it does not require ovarian stimulation and can be done without delay, which matters for patients who need to begin treatment quickly. It also does not require sexual maturity, making it an option for younger patients in some cases. ASCO now lists ovarian tissue cryopreservation among established methods, a change from its earlier experimental designation.
Ovarian Transposition
When pelvic radiation is part of the treatment plan, ovarian transposition (also called oophoropexy) is a surgical procedure that repositions the ovaries away from the radiation field to help shield them and preserve hormonal function. ASCO notes that this option is not suitable for patients with a moderate or high risk of cancer spreading to the ovaries, so it depends on the specific situation.
Fertility-Sparing Surgery
For some early-stage gynecologic cancers, surgical treatment can be tailored to preserve reproductive organs. These approaches are highly dependent on cancer type, stage, tumor size, and other features, and they are only appropriate for carefully selected patients.
For early-stage cervical cancer, fertility-sparing surgical options can include cone biopsy (conization), simple trachelectomy, or radical trachelectomy, procedures that remove the cancer while preserving the uterus. The appropriate option depends on factors such as the stage and size of the tumor.
For some early-stage endometrial cancers, progestin (hormone) therapy with regular monitoring may allow patients to delay or avoid hysterectomy while attempting pregnancy in appropriate cases.
For certain early-stage ovarian cancers, surgery that removes only the affected ovary while preserving the other may be possible, again depending on the tumor type and extent.
Whether any of these is appropriate is a decision made carefully between a patient and a gynecologic oncologist, weighing the goal of preserving fertility against the goal of fully treating the cancer.
Questions to Ask Your Care Team
If preserving fertility is important to you, raising it early gives you the most options. Some questions worth bringing to your care team:
- Could my recommended treatment affect my ability to have children?
- Can I be referred to a reproductive specialist before treatment begins?
- Which preservation options fit my cancer type and stage?
- How much time would fertility preservation add to my treatment timeline?
- Are there fertility-sparing surgical options for my specific diagnosis?
You can find more guidance in SERO’s list of questions to ask your radiation oncologist.
SERO’s Role
SERO‘s board-certified radiation oncologists treat gynecologic cancers as part of a multidisciplinary team that includes gynecologic oncologists and medical oncologists across the Charlotte region. When radiation is part of a patient’s treatment plan, fertility considerations are part of the conversation.
For patients who may benefit from ovarian transposition before pelvic radiation, SERO’s physicians coordinate closely with the surgical team so that timing and treatment planning align. Modern techniques such as intensity-modulated radiation therapy (IMRT) also allow radiation oncologists to shape treatment with precision, focusing dose on the cancer while limiting exposure to surrounding tissue. SERO’s team works to ensure that each patient understands how their treatment may affect fertility and what options exist before treatment begins.
Frequently Asked Questions
Can I still preserve fertility if I need to start treatment right away?
It depends on the method. Egg and embryo freezing require roughly two to four weeks for ovarian stimulation, while ovarian tissue cryopreservation does not require stimulation and can be done without that delay. This is one reason to discuss options with a reproductive specialist as early as possible, so the timing can be worked into your plan.
Does fertility preservation delay cancer treatment?
Some methods add time to the treatment timeline, and others add little or none. Your oncology team and a reproductive specialist can help you understand the tradeoffs for your specific situation and whether a short delay is safe given your diagnosis.
Is egg or embryo freezing safe for hormone-sensitive cancers?
For cancers sensitive to estrogen, stimulation protocols that include letrozole can prompt the ovaries to produce eggs without a large rise in estrogen, with results that appear comparable to standard stimulation. Whether this is right for you is a decision to make with your care team.
What if I’ve already started or finished treatment?
Fertility preservation is generally most effective before treatment, but it is still worth discussing afterward. ASCO notes that egg and embryo freezing may be offered after treatment to patients at risk of reduced fertility. A reproductive specialist can assess your situation.
Will I be able to carry a pregnancy after treatment?
This depends on which organs are affected and which treatments you receive. Some patients can carry a pregnancy after treatment, while others may pursue parenthood through options such as a gestational carrier. Your care team can give you the most accurate picture based on your individual diagnosis and plan.
If you or a loved one is facing a gynecologic cancer diagnosis and has questions about fertility, SERO’s team is here to help. Contact us to learn more about radiation therapy and your treatment options, or explore our patient resources for additional support.
